These known dysregulations in the ALK gene and their potential usefulness as biomarkers in many solid tumors, like inflammatory myofibroblastic tumors [24], esophageal squamous cell carcinoma [25] breast carcinoma [18] lung adenocarcinoma [9, 26] pediatric renal cell carcinoma [10] and neuroblastoma [27], have led to the development of ALK inhibitors and highlighted their therapeutic role in early clinical trials [18, 28, 29]. The gene discussed is ALK; the disease is esophageal squamous cell carcinoma.